

Copper–Catalyzed Amination in the Synthesis of Polyoxadiazamine Derivatives of Aza– and Diazacrown Ethers

Alexei A. Yakushev,^{a,c} Alexei D. Averin,^{a,b@} Maxim V. Anokhin,^b
Olga A. Maloshitskaya,^b Frédéric Lamaty,^c and Irina P. Beletskaya^{a,b}

^aA.N. Frumkin Institute of Physical Chemistry and Electrochemistry, 119991 Moscow, Russia

^bLomonosov Moscow State University, Department of Chemistry, 119991 Moscow, Russia

^cInstitut des Biomolécules Max Mousseron (IBMM) UMR 5247, Université Montpellier 2, 34095 Montpellier Cedex, France

@Corresponding author E-mail: alexaveron@yandex.ru

Cu(I)-Catalyzed amination of N-(iodobenzyl) substituted azacrown ethers with propane-1,3-diamine and several polyoxadiazamines was investigated. In the case of diamine excess and the use of CuI/l-proline catalytic system in EtCN the formation of the compounds with one azacrown and one diamine moieties was observed. When taking the excess of N-(iodobenzyl) derivative of azacrown ether and CuI/2-(isobutyryl)cyclohexanone catalytic system in DMF, bis(azacrown) substituted oxadiazamine could be obtained. Amination of N,N'-di(iodobenzyl) substituted diazacrown ether was studied under the same conditions. The comparison of Pd(0)- with Cu(I)-mediated amination reactions was done using N-(bromobenzyl) substituted azacrown ethers.

Keywords: Catalysis by Cu(I) complexes, amination, azacrown ethers, diamines.

Медь–катализируемое аминирование в синтезе полиоксадиаминовых производных аза– и диазакраун–эфиров

А. А. Якушев,^{a,c} А. Д. Аверин,^{a,b@} М. В. Анохин,^b О. А. Малошицкая,^b
Ф. Ламати,^c И. П. Белецкая^{a,b}

^aИнститут физической химии и электрохимии им. А.Н. Фрумкина, 119991 Москва, Россия

^bМосковский государственный университет им. М.В. Ломоносова, Химический факультет, 119991 Москва, Россия

^cInstitut des Biomolécules Max Mousseron (IBMM) UMR 5247, Университет Монпелье 2, 34095 Монпелье Седекс, Франция

@E-mail: alexaveron@yandex.ru

Изучено Cu(I)-катализируемое аминирование N-(иодбензил) замещенных азакраун-эфиров пропан-1,3-диамином и некоторыми полиоксадиаминами. При использовании избытка диаминов и каталитической системы CuI/l-пролин в EtCN наблюдалось образование соединений, содержащих один азакраун-эфирный и диаминовый фрагменты. При использовании избытка N-(иодбензил) производных азакраун-эфиров и каталитической системы CuI/2-(изобутирил)циклогексанон в ДМФА могут быть получены бис(азакраун) замещенные оксадиамины. Аминирование N,N'-ди(иодбензил) замещенного диазакраун-эфира исследовано в тех же условиях. Проведено сравнение Pd(0)- и Cu(I)-катализируемого аминирования с использованием N-(бромбензил) замещенных азакраун-эфиров.

Ключевые слова: Cu(I)-Катализ, аминирование, азакраун-эфиры, диамины.

Introduction

Oxygen- and nitrogen-containing macrocyclic compounds attract researchers' attention due to their unique properties of efficient and selective binding of metal cations, inorganic anions and small polar organic molecules. Introduction of additional donor atoms in the exocyclic substituents of such macrocycles may increase selectivity, binding constants and thus is widely used in coordination and supramolecular chemistry. One of the most important and renowned compounds of such type is *N,N',N'',N'''*-tetrasubstituted 1,4,7,10-tetraazacyclododecane (DOTA) bearing four carboxylic groups. It has been widely used in the coordination studies with various metal cations including rare earth metals and lanthanides.^[1-4] Well-studied are other tetrasubstituted tetraazamacrocycles like cyclen and cyclam (1,4,8,11-tetraazacyclotetradecane) with phosphonate,^[5-10] amide,^[11] nitrile,^[12] primary and tertiary amino groups.^[13,14] In many cases additional donor atoms are present in C-substituted macrocycles like cyclam^[15,16] or crown ethers.^[17] Special interest is paid to substituents bearing several donor atoms (podands), among them oligoethylene oxides are very attractive due to an easy introduction of such podands into macrocycles, possibility to vary the number of donor atoms and their non-ionogenic character. Aza-crown ethers are usually modified with these podands at the nitrogen atom,^[18-20] while crown ethers may contain these substituents only at carbon atoms.^[21-23] We have developed a simple and efficient approach to macrobicycles and trismacrocycles compounds using Pd(0)-catalyzed macrocyclization of *N,N'*-di(bromobenzyl) substituted diazacrown ethers with polyamines and polyoxadiazamines,^[24,25] also we carried out the synthesis of various bismacrocycles based on *N*-benzyl substituted azacrown ethers.^[26] Recently we have started thorough investigation of Cu(I)-catalyzed arylation and heteroarylation of polyamines and polyoxadiazamines^[27-29] as well as Cu(I)-mediated amination of steroids.^[30] In this connection, the aim of the present research is to apply Cu(I)-catalyzed amination to the synthesis of polyoxadiazamine derivatives of aza- and diazacrown ethers and to compare it with the approach which exploits Pd(0) catalysis.

Experimental

NMR spectra were registered using Bruker Avance 400 spectrometer, MALDI-TOF spectra were obtained with Bruker Autoflex II spectrometer using 1,8,9-trihydroxyanthracene as matrix and PEGs as internal standards. Propane-1,3-diamine, dioxane and trioxadiazamines, aza- and diazacrown ethers, 1-(bromomethyl)-3-bromobenzene, *l*-proline, 2-isobutyrylcyclohexanone, BINAP, cesium carbonate, potassium carbonate, sodium *tert*-butoxide, CuI were purchased from Aldrich and used without further purification, Pd(dba)₂ was synthesized according to the method described,^[31] 1-(bromomethyl)-3-iodobenzene was obtained from commercially available *m*-iodotoluene by a standard bromination with NBS in CCl₄. Dioxane was distilled over NaOH followed by the distillation over sodium under argon, acetonitrile was distilled over CaH₂, DMF, EtCN, dichloromethane and methanol were used freshly distilled.

Typical procedure for the synthesis of aza- and diazacrown derivatives 1-4, 9. A flask equipped with a condenser and magnetic stirrer was charged with corresponding azacrown ether (1 mmol), MeCN (3 ml), 1-(bromomethyl)-3-bromobenzene or 1-(bromomethyl)-3-iodobenzene (1 mmol), potassium carbonate

(2.5 mmol) and stirred under reflux for 15 h. In the case of compound **9** diaza-18-crown-6 ether (1 mmol) was reacted with 1-(bromomethyl)-3-iodobenzene (2 mmol) in the presence of potassium carbonate (4 mmol). After cooling the reaction mixture down to room temperature the reaction mixture was diluted with CH₂Cl₂ (10 ml), the solution was filtered, evaporated *in vacuo*, dissolved in CH₂Cl₂ (10 ml), washed with an equal volume of water and dried over molecular sieves. After evaporating the solvent, target *N*-halogenobenzyl derivatives of aza- and diazacrown ethers were obtained as viscous yellowish oils.

13-(3-Bromobenzyl)-1,4,7,10-tetraoxa-13-azacyclodecane (1). Obtained from 1-aza-15-crown-5 (2 mmol, 438 mg) and 3-bromobenzyl bromide (2 mmol, 500 mg) in the presence of K₂CO₃ (5 mmol, 695 mg) in 7 ml MeCN. Yield 728 mg (94 %). (MALDI-TOF) found: 388.1167. C₁₇H₂₇BrNO₄ requires 388.1123 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 2.76 (4H, t, ³J = 5.8 Hz), 3.60-3.64 (10H, m), 3.65-3.69 (8H, m), 7.13 (1H, t, ³J = 7.8 Hz), 7.24 (1H, d, ³J = 7.8 Hz), 7.33 (1H, d, ³J = 7.8 Hz), 7.51 (1H, s). ¹³C NMR (CDCl₃, 298 K) δ_C ppm: 54.2 (2C), 60.1 (1C), 69.9 (2C), 70.2 (2C), 70.5 (2C), 70.9 (2C), 122.4 (1C), 127.3 (1C), 129.7 (1C), 129.9 (1C), 131.6 (1C), 142.3 (1C).

16-(3-Bromobenzyl)-1,4,7,10,13-pentaoxa-16-azacyclooctadecane (2). Obtained from 1-aza-18-crown-6 (1 mmol, 263 mg) and 3-bromobenzyl bromide (1 mmol, 250 mg) in the presence of K₂CO₃ (2.5 mmol, 348 mg) in 4 ml MeCN. Yield 415 mg (96 %). (MALDI-TOF) found: 432.1425. C₁₉H₃₁BrNO₅ requires 432.1386 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 2.76 (4H, t, ³J = 5.3 Hz), 3.57-3.62 (8H, m), 3.63-3.69 (14H, m), 7.13 (1H, t, ³J = 7.7 Hz), 7.24 (1H, d, ³J = 8.0 Hz), 7.32 (1H, d, ³J = 7.6 Hz), 7.50 (1H, s). ¹³C NMR (CDCl₃, 298 K) δ_C ppm: 53.9 (2C), 59.5 (1C), 69.9 (2C), 70.4 (2C), 70.8 (4C), 70.9 (2C), 122.4 (1C), 127.3 (1C), 129.7 (1C), 129.9 (1C), 131.6 (1C), 142.5 (1C).

13-(3-Iodobenzyl)-1,4,7,10-tetraoxa-13-azacyclodecane (3). Obtained from 1-aza-15-crown-5 (4 mmol, 876 mg) and 3-iodobenzyl bromide (4 mmol, 1188 mg) in the presence of K₂CO₃ (8 mmol, 1104 mg) in 12 ml MeCN. Yield 1.600 g (92 %). (MALDI-TOF) found: 436.0932. C₁₇H₂₇INO₄ requires 436.0985 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 2.70 (4H, t, ³J = 5.9 Hz), 3.54-3.59 (10H, m), 3.60-3.64 (8H, m), 6.96 (1H, t, ³J = 7.7 Hz), 7.23 (1H, d, ³J = 7.6 Hz), 7.49 (1H, d, ³J = 7.8 Hz), 7.65 (1H, s).

16-(3-Iodobenzyl)-1,4,7,10,13-pentaoxa-16-azacyclooctadecane (4). Obtained from 1-aza-18-crown-6 (1 mmol, 263 mg) and 3-iodobenzyl bromide (1 mmol, 297 mg) in the presence of K₂CO₃ (2.5 mmol, 348 mg) in 4 ml MeCN. Yield 445 mg (93 %). (MALDI-TOF) found: 480.1289. C₁₉H₃₁INO₅ requires 480.1247 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 2.76 (4H, t, ³J = 5.7 Hz), 3.59-3.64 (10H, m), 3.64-3.70 (12H, m), 7.01 (1H, t, ³J = 7.7 Hz), 7.29 (1H, d, ³J = 7.7 Hz), 7.54 (1H, d, ³J = 7.8 Hz), 7.70 (1H, s). ¹³C NMR (CDCl₃, 298 K) δ_C ppm: 53.9 (2C), 59.4 (1C), 69.9 (2C), 70.4 (2C), 70.8 (4C), 70.9 (2C), 104.5 (1C), 128.0 (1C), 129.9 (1C), 135.9 (1C), 137.6 (1C), 142.6 (1C).

7,16-Bis(3-iodobenzyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecane (9). Obtained from diaza-18-crown-6 (4 mmol, 1.060 g) and 3-iodobenzyl bromide (8 mmol, 2.376 g) in the presence of Na₂CO₃ (16 mmol, 1.696 g) in 15 ml MeCN. Yield 2.498 g (90 %). (MALDI-TOF) found: 695.0802. C₂₆H₃₇I₂N₂O₄ requires 695.0843 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 2.76 (8H, t, ³J = 5.3 Hz), 3.52-3.65 (20H, m), 6.98 (2H, t, ³J = 7.7 Hz), 7.26 (2H, d, ³J = 7.7 Hz), 7.51 (2H, d, ³J = 7.7 Hz), 7.67 (2H, s).

Typical procedure for the Cu(I)-catalyzed amination of compounds 3, 4, 9. A two-necked flask equipped with a condenser and magnetic stirrer was flushed with argon, charged with corresponding azacrown ether derivative **3**, **4**, **9** (0.5 mmol for the monoamination or diamination or 1 mmol for the diarylation), CuI (10 mol% for the monoamination or 20 mol% for the diamination and diarylation), *l*-proline or 2-isobutyrylcyclohexanone (20 mol% for the monoamination or 40 mol% for the diamination and diarylation), EtCN or DMF (1 ml), corresponding diamine/

oxadiazine (1 mmol for the monoamination, 2 mmol for the diamination, or 0.5 mmol for the arylation), cesium carbonate (1.5 equiv. for each NH₂ group participating in the arylation). The reaction mixture was stirred under reflux (EtCN) or at 140 °C (DMF) for 24 h. After cooling the reaction mixture down to room temperature the reaction mixture was diluted with CH₂Cl₂ (10 ml), the solution was filtered, evaporated *in vacuo*, dissolved in CH₂Cl₂ (10 ml), and additional precipitate was separated. After evaporating the solvent, the residue was chromatographed on silica gel using a sequence of eluents: CH₂Cl₂, CH₂Cl₂/MeOH (50:1–3:1), CH₂Cl₂/MeOH/NH₃aq (100:20:1–10:4:1).

Typical procedure for the Pd(0)-catalyzed synthesis of compounds 7a,b. A two-necked flask equipped with a condenser and magnetic stirrer was flushed with argon, charged with corresponding azacrown ether derivative **1** or **2** (0.5 mmol), Pd(dba)₂ (4 mol%, 12 mg), BINAP (4.5 mol%, 14 mg), absolute dioxane (10–20 ml), propane-1,3-diamine (1.5 or 2 mmol, 111 or 148 mg) was added followed by sodium *tert*-butoxide (0.75 mmol, 72 mg). The reaction mixture was refluxed for 8 h, after cooling the reaction mixture down to room temperature the reaction mixture was diluted with CH₂Cl₂ (10 ml), the solution was filtered, evaporated *in vacuo*, dissolved in CH₂Cl₂ (10 ml), and additional precipitate was separated. After evaporating the solvent, the residue was chromatographed on silica gel using a sequence of eluents: CH₂Cl₂, CH₂Cl₂/MeOH (50:1–3:1), CH₂Cl₂/MeOH/NH₃aq (100:20:1–10:4:1) to produce target compounds as viscous yellowish oils or glassy solids.

*N*¹-(3-((1,4,7,10-Tetraoxa-13-azacyclopentadecan-13-yl)methyl)phenyl)propane-1,3-diamine (**6a**). Obtained from compound **1** (1 mmol, 388 mg), propane-1,3-diamine (**5a**) (3 mmol, 222 mg), in the presence of Pd(dba)₂ (4 mol%, 24 mg), BINAP (4.5 mol%, 28 mg), *t*BuONa (1.5 mmol, 144 mg) in 20 ml dioxane. Eluent: CH₂Cl₂/MeOH/NH₃aq (100:25:5–100:35:6). Yield 221 mg (58 %). (MALDI-TOF) found: 382.2670. C₂₀H₃₆N₃O₄ requires 382.2706 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 1.75 (2H, quintet, ³J = 6.6 Hz), 2.73 (4H, t, ³J = 5.7 Hz), 2.79 (2H, br. t, ³J_{obs} = 6.2 Hz), 3.14 (2H, t, ³J = 6.6 Hz), 3.56 (2H, s), 3.57–3.65 (16H, m), 6.44 (1H, dd, ³J = 7.8 Hz, ⁴J = 1.0 Hz), 6.56 (1H, d, ³J = 7.3 Hz), 6.67 (1H, s), 7.04 (1H, t, ³J = 7.7 Hz). (Three NH protons were not assigned). ¹³C NMR (CDCl₃, 298 K) δ_C ppm: 32.1 (1C), 39.8 (1C), 41.7 (1C), 54.2 (2C), 60.7 (1C), 69.5 (2C), 69.9 (2C), 70.0 (2C), 70.6 (2C), 110.7 (1C), 113.7 (1C), 117.7 (1C), 128.8 (1C), 140.0 (1C), 148.5 (1C).

*N*¹-(3-((1,4,7,10,13-Pentaoxa-16-azacyclooctadecan-16-yl)methyl)phenyl)propane-1,3-diamine (**7a**). Obtained from compound **2** (0.9 mmol, 389 mg), propane-1,3-diamine (**5a**) (3.6 mmol, 266 mg), in the presence of Pd(dba)₂ (4 mol%, 21 mg), BINAP (4.5 mol%, 25 mg), *t*BuONa (1.4 mmol, 134 mg) in 9 ml dioxane. Eluent: CH₂Cl₂/MeOH (3:1). Yield 178 mg (46%). (MALDI-TOF) found: 426.2995. C₂₂H₄₀N₃O₅ requires 426.2968 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 1.79 (2H, quintet, ³J = 6.5 Hz), 2.72 (4H, t, ³J = 5.6 Hz), 2.87 (2H, t, ³J = 6.6 Hz), 3.14 (2H, t, ³J = 6.4 Hz), 3.52 (2H, s), 3.55–3.65 (20H, m), 6.43 (1H, dd, ³J = 7.8 Hz, ⁴J = 1.1 Hz), 6.53 (1H, d, ³J = 7.5 Hz), 6.59 (1H, s), 7.01 (1H, t, ³J = 7.8 Hz). (Three NH protons were not assigned). ¹³C NMR (CDCl₃, 298 K) δ_C ppm: 31.0 (1C), 39.3 (1C), 41.4 (1C), 54.0 (2C), 59.6 (1C), 69.6 (2C), 70.2 (2C), 70.5 (4C), 70.7 (2C), 110.9 (1C), 113.5 (1C), 117.5 (1C), 128.8 (1C), 140.0 (1C), 148.5 (1C).

*N*¹,*N*³-bis(3-((1,4,7,10,13-Pentaoxa-16-azacyclooctadecan-16-yl)methyl)phenyl)propane-1,3-diamine (**8a**) was obtained as the second product in the synthesis of compound **7a** from compound **2** (0.92 mmol, 396 mg), propane-1,3-diamine (**5a**) (2.7 mmol, 200 mg), in the presence of Pd(dba)₂ (4 mol%, 21 mg), BINAP (4.5 mol%, 26 mg), *t*BuONa (1.4 mmol, 134 mg) in 10 ml dioxane. CH₂Cl₂/MeOH/NH₃aq (100:35:6). Yield 30 mg (8 %). (MALDI-TOF) found: 777.48. C₄₁H₆₉N₄O₁₀ requires 777.50 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 1.90 (2H, quintet, ³J = 6.7 Hz), 2.75 (8H, t, ³J = 5.6 Hz), 3.22 (4H, t, ³J = 6.6 Hz), 3.55–3.67 (44H, m), 3.90 (2H, br. s), 6.46 (2H, d, ³J = 7.7 Hz), 6.60 (2H, d, ³J = 7.5 Hz), 6.65 (2H, s), 7.06 (2H, t, ³J = 7.5 Hz). ¹³C NMR (CDCl₃, 298 K) δ_C ppm:

29.2 (1C), 41.9 (2C), 54.0 (4C), 60.0 (2C), 69.8 (4C), 70.2 (4C), 70.6 (8C), 70.7 (4C), 110.9 (2C), 113.5 (2C), 117.8 (2C), 128.9 (2C), 140.6 (2C), 148.3 (2C).

3-((1,4,7,10-Tetraoxa-13-azacyclopentadecan-13-yl)methyl)-*N*-(2-(2-(2-aminoethoxy)ethoxy)ethyl)aniline (**6b**). Obtained from compound **3** (0.15 mmol, 66 mg), dioxadiazine (**5b**) (0.3 mmol, 44 mg), in the presence of CuI (10 mol%, 3 mg), *l*-proline (20 mol%, 3.5 mg), Cs₂CO₃ (0.225 mmol, 73 mg) in 1 ml EtCN. Eluent: CH₂Cl₂/MeOH (3:1), CH₂Cl₂/MeOH/NH₃aq (100:20:1–100:20:3). Yield 51 mg (75 %). (MALDI-TOF) found: 456.3132. C₂₃H₄₂N₃O₆ requires 456.3074 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 3.03 (2H, br. s), 3.19 (4H, bs), 3.35 (2H, t, ³J = 4.8 Hz), 3.59–3.70 (20H, m), 3.74 (2H, t, ³J = 4.8 Hz), 3.82 (4H, t, ³J = 4.7 Hz), 4.02 (1H, bs), 6.56–6.63 (2H, m), 7.14 (1H, t, ³J = 7.7 Hz), 7.22 (1H, bs). (NH₂ protons were not assigned). ¹³C NMR (CDCl₃, 298 K) δ_C ppm: 39.5 (1C), 43.3 (1C), 53.7 (2C), 56.7 (1C), 66.5 (2C), 68.4–70.1 (10C, m), 112.0 (1C), 116.2 (1C), 119.3 (1C), 129.5 (1C), 136.9 (1C), 149.0 (1C).

3-((1,4,7,10-Tetraoxa-13-azacyclopentadecan-13-yl)methyl)-*N*-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)aniline (**6c**). Obtained from compound **3** (0.15 mmol, 66 mg), trioxadiazine (**5c**) (0.3 mmol, 58 mg), in the presence of CuI (10 mol%, 3 mg), *l*-proline (20 mol%, 3.5 mg), Cs₂CO₃ (0.225 mmol, 73 mg) in 1 ml EtCN. Eluent: CH₂Cl₂/MeOH (3:1). Yield 25 mg (33 %). (MALDI-TOF) found: 500.3301. C₂₅H₄₆N₃O₇ requires 500.3336 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 2.81 (2H, bs), 2.87 (4H, br. s), 3.25 (2H, t, ³J = 4.7 Hz), 3.55–3.69 (26H, m), 3.71 (2H, t, ³J = 5.1 Hz), 3.78 (2H, t, ³J = 5.1 Hz), 4.12 (1H, bs), 6.53 (2H, d, ³J = 8.0 Hz), 7.09 (1H, t, ³J = 7.7 Hz), 7.09 (1H, s). (NH₂ protons were not assigned). ¹³C NMR (CDCl₃, 298 K) δ_C ppm: 39.6 (1C), 43.6 (1C), 53.9 (2C), 58.7 (1C), 66.3 (2C), 68.2 (1C), 68.9–70.4 (11C, m), 111.6 (1C), 116.3 (1C), 119.5 (1C), 129.3 (1C), 136.6 (1C), 149.0 (1C).

3-((1,4,7,10-Tetraoxa-13-azacyclopentadecan-13-yl)methyl)-*N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)aniline (**6d**). Obtained from compound **3** (0.29 mmol, 128 mg), trioxadiazine (**5d**) (0.58 mmol, 128 mg), in the presence of CuI (10 mol%, 5.5 mg), *l*-proline (20 mol%, 6.7 mg), Cs₂CO₃ (0.435 mmol, 142 mg) in 2 ml EtCN. Eluent: CH₂Cl₂/MeOH (5:1–3:1). Yield 57 mg (37 %). (MALDI-TOF) found: 528.3577. C₂₇H₅₀N₃O₇ requires 528.3649 [M+H]⁺. ¹H NMR (CD₃OD, 298 K) δ_H ppm: 1.88 (4H, quintet, ³J = 6.1 Hz), 2.72 (4H, t, ³J = 4.5 Hz), 3.03 (2H, bs), 3.19 (2H, t, ³J = 6.6 Hz), 3.56–3.72 (30H, m), 6.55 (1H, d, ³J = 7.1 Hz), 6.59 (1H, s), 6.60 (1H, d, ³J = 8.0 Hz), 7.11 (1H, t, ³J = 7.5 Hz). (NH protons were not observed). ¹³C NMR (CD₃OD, 298 K) δ_C ppm: 28.9 (1C), 29.4 (1C), 38.6 (1C), 40.8 (1C), 53.0 (2C), 57.7 (1C), 66.9 (2C), 68.0 (1C), 68.5–70.1 (9C, m), 111.8 (1C), 114.8 (1C), 118.6 (1C), 129.0 (1C), 136.2 (1C), 149.1 (1C).

3-((1,4,7,10,13-Pentaoxa-16-azacyclooctadecan-16-yl)methyl)-*N*-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)aniline (**7d**). Obtained from compound **4** (0.5 mmol, 222 mg), trioxadiazine (**5d**) (1 mmol, 220 mg), in the presence of CuI (10 mol%, 9.5 mg), *l*-proline (20 mol%, 10.5 mg), Cs₂CO₃ (1.5 mmol, 489 mg) in 2 ml EtCN. Eluent: CH₂Cl₂/MeOH/NH₃aq (100:20:1–100:20:3). Yield 185 mg (65 %). (MALDI-TOF) found: 572.3950. C₂₉H₅₄N₃O₈ requires 572.3911 [M+H]⁺. ¹H NMR (CDCl₃, 328 K) δ_H ppm: 1.76 (2H, quintet, ³J = 6.8 Hz), 1.83 (2H, quintet, ³J = 6.0 Hz), 2.85–2.94 (6H, m), 3.18 (2H, t, ³J = 6.4 Hz), 3.50 (2H, t, ³J = 5.7 Hz), 3.50–3.64 (28H, m), 3.69 (4H, bs), 6.47 (1H, d, ³J = 7.5 Hz), 6.50 (1H, d, ³J = 8.0 Hz), 6.65 (1H, s), 7.02 (1H, t, ³J = 7.7 Hz). (NH protons were not assigned). ¹³C NMR (CDCl₃, 298 K) δ_C ppm: 27.9 (1C), 29.2 (1C), 37.7 (1C), 41.6 (1C), 54.2 (2C), 57.0 (1C), 66.9 (2C), 68.1 (1C), 69.5–70.5 (13C, m), 112.0 (1C), 114.8 (1C), 118.1 (1C), 129.2 (1C), 149.2 (1C). (One aromatic quaternary carbon was not assigned).

*N*¹,*N*^{1'}-(3,3'-(1,4,10,13-Tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene)bis(3,1-phenylene))dipropane-1,3-diamine (**10a**). Obtained from compound **9** (0.15 mmol, 104 mg),

propane-1,3-diamine (**5a**) (0.6 mmol, 44 mg), in the presence of CuI (20 mol%, 6 mg), *l*-proline (40 mol%, 7 mg), Cs₂CO₃ (0.45 mmol, 147 mg) in 1 ml EtCN. Eluent: CH₂Cl₂/MeOH/NH₃aq (100:35:6–10:4:1). Yield 52 mg (36 %). (MALDI-TOF) found: 587.4349. C₃₂H₅₅N₆O₄ requires 587.4285 [M+H]⁺. ¹H NMR (CD₃OD, 298 K) δ_H ppm: 1.79 (4H, quintet, ³J = 7.0 Hz), 2.71 (8H, t, ³J = 4.9 Hz), 2.81 (4H, t, ³J = 6.5 Hz), 3.17 (4H, t, ³J = 6.5 Hz), 3.51 (4H, s), 3.54 (8H, s), 3.61 (8H, t, ³J = 4.9 Hz), 6.47 (2H, d, ³J = 7.2 Hz), 6.53 (2H, s), 6.54 (2H, d, ³J = 7.6 Hz), 7.06 (2H, t, ³J = 7.7 Hz). (NH protons were not assigned). ¹³C NMR (CD₃OD, 298 K) δ_C ppm: 31.8 (2C), 39.9 (2C), 42.0 (2C), 55.2 (4C), 58.6 (2C), 69.8 (4C), 71.3 (4C), 112.5 (2C), 115.7 (2C), 119.4 (2C), 130.0 (2C), 139.3 (2C), 150.0 (2C).

3,3'-(1,4,10,13-Tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene)bis(*N*-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)aniline (**10d**). Obtained from compound **9** (0.5 mmol, 347 mg), trioxadiazamine (**5d**) (2 mmol, 440 mg), in the presence of CuI (20 mol%, 20 mg), *l*-proline (40 mol%, 24 mg), Cs₂CO₃ (2 mmol, 652 mg) in 1 ml EtCN. Yield in the reaction mixture 76%. (MALDI-TOF) found: 823.58. C₄₂H₇₅N₆O₁₀ requires 823.55 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 1.63 (4H, bs), 1.79 (4H, quintet, ³J = 6.1 Hz), 2.66 (8H, bs), 2.70 (4H, bs), 3.10 (4H, t, ³J = 6.1 Hz), 3.40-3.56 (32H, m), 6.38 (2H, d, ³J = 7.7 Hz), 6.46 (2H, d, ³J = 6.8 Hz), 6.52 (2H, s), 6.98 (2H, t, ³J = 7.7 Hz). (NH protons were not assigned).

3-((1,4,7,10-Tetraoxa-13-azacyclopentadecan-13-yl)methyl)-*N*-(3-(2-(2-(3-(4-((1,4,7,10-tetraoxa-13-azacyclopentadecan-13-yl)methyl)phenylamino)propoxy)ethoxy)ethoxy)propyl)aniline (**11d**). Obtained from compound **3** (0.78 mmol, 340 mg), trioxadiazamine (**5d**) (0.39 mmol, 85 mg), in the presence of CuI (20 mol%, 15 mg), 2-(isobutyryl)cyclohexanone (40 mol%, 26 mg), Cs₂CO₃ (1.5 mmol, 489 mg) in 1 ml DMF. Eluent: CH₂Cl₂/MeOH/NH₃aq (100:20:2). Yield 92 mg (28 %). (MALDI-TOF) found: 835.5380. C₄₄H₇₅N₄O₁₁ requires 835.5432 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 1.86 (4H, quintet, ³J = 6.3 Hz), 2.77 (8H, t, ³J = 5.8 Hz), 3.19 (4H, t, ³J = 6.6 Hz), 6.44 (2H, dd, ³J = 7.8 Hz, ⁴J = 1.3 Hz), 6.59 (2H, d, ³J = 7.6 Hz), 6.62 (2H, s), 7.05 (2H, t, ³J = 7.8 Hz). (NH protons were not assigned). ¹³C NMR (CDCl₃, 298 K) δ_C ppm: 29.2 (2C), 41.6 (2C), 54.3 (4C), 60.8 (2C), 69.6 (2C), 69.8 (4C), 70.1 (4C), 70.2 (2C), 70.4 (4C), 70.6 (2C), 70.8 (4C), 111.0 (2C), 113.4 (2C), 117.6 (2C), 128.9 (2C), 140.4 (2C), 148.6 (2C).


N,N'-(3,3'-(2,2'-Oxybis(ethane-2,1-diyl)bis(oxy))bis(propane-3,1-diyl)bis(3-(16-(3-iodobenzyl)-1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-yl)methyl)aniline) (**12d**). Obtained from compound **9** (1 mmol, 694 mg), trioxadiazamine (**5d**) (0.5 mmol, 110 mg), in the presence of CuI (20 mol%, 19 mg), 2-(isobutyryl)cyclohexanone (40 mol%, 34 mg), Cs₂CO₃ (1.5 mmol, 489 mg) in 1 ml DMF. Eluent: CH₂Cl₂/MeOH/NH₃aq (100:25:1-100:25:2). Yield 120 mg (18 %). (MALDI-TOF) found: 1353.54. C₆₂H₉₅I₂N₆O₁₁ requires 1353.51 [M+H]⁺. ¹H NMR (CDCl₃, 298 K) δ_H ppm: 1.86 (4H, quintet, ³J = 5.9 Hz), 2.74-2.86 (16H, m), 3.19 (4H, t, ³J = 6.4 Hz), 3.51-3.70 (40H, m), 6.45 (2H, d, ³J = 7.2 Hz), 6.58 (2H, s), 6.62 (2H, d, ³J = 7.3 Hz), 7.00 (2H, t, ³J = 7.6 Hz), 7.06 (2H, t, ³J = 7.5 Hz), 7.29 (2H, d, ³J = 7.3 Hz), 7.53 (2H, d, ³J = 7.3 Hz), 7.69 (2H, s). (NH protons were not

assigned). ¹³C NMR (CDCl₃, 298 K) δ_C ppm: 29.2 (2C), 41.6 (2C), 53.6 (4C), 53.7 (4C), 59.2 (2C), 60.0 (2C), 69.7 (2C), 69.9 (8C), 70.2 (2C), 70.6 (8C), 94.3 (1C), 111.2 (2C), 113.3 (2C), 117.7 (2C), 127.9 (2C), 128.9 (2C), 129.9 (2C), 135.8 (2C), 137.5 (2C), 141.8 (2C), 142.4 (2C), 148.5 (2C).


Results and Discussion

Initially 1-aza-15-crown-5 and 1-aza-18-crown-6 were modified with 3-bromobenzyl or 3-iodobenzyl substituents using simple nucleophilic substitution reactions with corresponding benzyl bromides (Scheme 1). Target products **1-4** were obtained in high yields (92-96 %) after simple work-up of the reaction mixtures.

First bromobenzyl derivatives of azacrown ethers **1** and **2** were employed in the Pd(0)-catalyzed reactions with 3 equiv. of propane-1,3-diamine **5a** to check the selectivity of the *N*-monoarylation vs *N,N'*-diarylation and to elaborate the conditions for the chromatographic isolation of the target products. Standard conditions for these processes were applied: Pd(dba)₂/BINAP catalytic system (4/4.5 mol%), 1.5 equiv. *t*BuONa as a base. The amination of compound **1** using 0.02 M solution of **1** led to 85 % yield of the monoarylation product **6a**, and after column chromatography it was isolated in 43 % yield, whereas the same reaction in a more concentrated solution (*C* = 0.05 M) led to 87 % yield of the target compound **6a** in the reaction mixture and 58 % yield after chromatography. In the case of compound **2** the similar reaction led to 77 % yield of the product of monoarylation **7a** and 23 % yield of the diarylated diamine **8a**. After column chromatography their yields were 30 and 8 % respectively (Scheme 2). The application of 4 equiv. of propane-1,3-diamine in the reaction with compound **2** resulted in 88 % yield of the target compound **7a** in the reaction mixture, thus it can be used *in situ* for some further transformations. The yield after chromatography in this case also increased to 46 %. Amination reactions were also conducted with iodobenzyl derivative **4** using either CuI/L1 (10/20 mol%) catalytic system (L1 = *l*-proline), 1.5 equiv. Cs₂CO₃ in boiling EtCN (*C* = 0.5 M), or CuI/L2 (10/20 mol%) catalytic system (L2 = 2-isobutyrylcyclohexanone), 1.5 equiv. Cs₂CO₃ in DMF (140 °C). The first reaction afforded 80 % yield of the compound **7a** in the reaction mixture and 22 % after chromatographic isolation, the second reaction produced 17 % of the same compound after chromatography. No product of diarylation **8a** was noted in both cases. For this reason we chose CuI/L1/EtCN for further syntheses of monoaryl derivatives of polyoxadiazamines. It should be noted that as the excess of propane-1,3-diamine can easily be removed in high vacuum and only 2 equiv. of this diamine



Scheme 1.



Scheme 2.


are needed to form the monoarylated derivative **7a**, in the case of further transformations of this compound one does not need its chromatographic purification and may use it *in situ*.

Further Cu(I)-catalyzed reactions were conducted using iodobenzyl derivatives **3** and **4** and a number of di- and trioxadiazacrowns **5b-c** taken in two-fold excess (Scheme 3). These reactions were catalyzed by CuI/L1 (10/20 mol%) in the presence of Cs₂CO₃ in EtCN and the products were isolated by column chromatography. Dioxadiazacrown **5b** afforded 75 % yield of the target compound **6b**, while the reactions with trioxadiazacrowns **5c,d** gave lower yields of corresponding derivatives **6c,d** (33 and 37 %). The amination of compound **4** with trioxadiazacrown **5d** was much more successful and the product **7d** was obtained in 65 % yield. No products of *N,N'*-diarylation of polyoxadiazacrowns were isolated in all cases. This fact is in a good correspondence with our previous results of the Cu-catalyzed arylation of polyoxadiazacrowns.^[27] In this research we did not use polyamines as substrates though they were found to participate better than oxadiazacrowns in the copper-catalyzed arylation and heteroarylation reactions.^[27,28] This was done in view of a practical impos-


sibility of the isolation of their pure monoaryl derivatives bearing azacrown moiety from the reaction mixture with the excess of polyamine.

Next we investigated the possibility to introduce diazacrown ethers in the reactions with propane-1,3-diamine and oxadiazacrowns. *N,N'*-di(3-iodobenzyl) derivative of diaza-18-crown-6 **9** was synthesized in 90 % yield, and it was introduced in the reaction with 4 equiv. of propane-1,3-diamine catalyzed by CuI/L1 (20/40 mol%) (Scheme 4). The yield of the target compound **10a** exceeded 80 % in the reaction mixture, and after column chromatography it was 36 %. The same reaction with trioxadiazacrown **5d** afforded 76 % yield of the bis(trioxadiazacrown) derivative **10d** in the reaction mixture.


According to our previous investigations, the copper-catalyzed *N,N'*-diarylation of diamines and oxadiazacrowns turned to be a challenging task. We carried out the diarylation of trioxadiazacrown **5d** using 2 equiv. of iodobenzyl substituted azacrown **3** (Scheme 5). In this case the catalytic system CuI/L2 in DMF (140 °C) was employed because we had shown it to promote *N,N'*-diarylation of oxadiazacrowns with simple aryl



Scheme 3.



Scheme 4.



Scheme 5.

iodides.^[27] The target product **11d** was isolated in 28 % yield. The same reaction with tetraamine **5e** catalyzed by CuI/L1 in DMF gave a complex mixture of the products of arylation among which the target compound was detected by NMR and MALDI-TOF spectroscopy, however, the pure product could not be isolated by column chromatography, probably due to the formation of isomers with close R_f . Similarly, the reaction of *N,N'*-di(3-iodobenzyl) substituted diazocrown **9** produced corresponding bisazacrown derivative of trioxadiazacrown **12d**, but the reaction with tetraamine **5e** gave only an inseparable mixture of unidentified compounds.

Conclusions

To sum up, we investigated the possibility to modify azacrown ethers with propane-1,3-diamine and polyoxadiazacrown podands using Cu(I)-catalyzed amination and found out that this approach is quite applicable. The reactions mediated by Cu(I) and Pd(0) were shown to produce the target arylation products in comparable yields. Moderate yields of the target compounds were due to their

difficult isolation using column chromatography, and in the case of propane-1,3-diamine its excess can be removed *in vacuo*, and the product was shown to be enough pure for further transformations. Cu(I)-catalyzed diamination of the diazocrown derivative was also demonstrated as well as *N,N'*-diarylation of trioxadiazacrown ethers. Only diamines and polyoxadiazacrown podands but not polyamines can be employed in these reactions.

Acknowledgements. This work was financially supported by the RFBR grants 12-03-00796, 12-03-93113, and by the Russian Academy of Sciences program P-8 "Development of the methods for the synthesis of new chemicals and creation of new materials".

References

1. Caceris W.P., Nickle S.K., Sherry A.D. *Inorg. Chem.* **1987**, *26*, 958-960.
2. Hama H., Takamoto S. *Nippon Kagaku Kaishi* **1975**, 1182-1185.

3. Stetter H., Frank W. *Angew. Chem., Int. Ed. Engl.* **1976**, *15*, 686-686.
4. Brucher E., Laurency G., Makra Z.S. *Inorg. Chim. Acta* **1987**, *139*, 141-142.
5. Medved T.Ya., Kabachnik M.I., Belskii F.I., Pisareva S.A. *Izv. Akad. Nauk SSSR, Ser. Khim.* **1988**, 2103-2107 (in Russ.).
6. Polikarpov Yu.M., Belskii F.I., Pisareva S.A., Kabachnik M.I. *Izv. Akad. Nauk SSSR, Ser. Khim.* **1989**, 2112-2116 (in Russ.).
7. Kabachnik M.I., Medved T.Ya., Belskii F.I., Pisareva S.A. *Izv. Akad. Nauk SSSR, Ser. Khim.* **1984**, 844-849 (in Russ.).
8. Delgado R., Siegfried L.C., Kaden T.A. *Helv. Chim. Acta* **1990**, *73*, 140-148.
9. Kabachnik M.I., Polikarpov Yu.M. *J. Gen. Chem. USSR (Engl. Transl.)* **1988**, *58*, 1729-1750.
10. Pisareva S.A., Belskii F.I., Medved T.Ya., Kabachnik M.I. *Izv. Akad. Nauk SSSR, Ser. Khim.* **1987**, 413-417 (in Russ.).
11. Katakya R., Matthes K.E., Nicholson P.E., Parker D., Buschmann H.J. *J. Chem. Soc., Perkin Trans. 2* **1990**, 1425-1432.
12. Izatt R.M., Pawlak K., Bradshaw J.S. *Chem. Rev.* **1991**, *91*, 1721-2085.
13. Basak A.K., Kaden T.A. *Helv. Chim. Acta* **1983**, *66*, 2086-2092.
14. Evers A., Hancock R.D., Murase I. *Inorg. Chem.* **1986**, *25*, 2160-2163.
15. Kimura E., Machida R., Kodama M. *J. Am. Chem. Soc.* **1984**, *106*, 5497-5505.
16. Fujioka H., Kimura E., Kodama M. *Chem. Lett.* **1982**, 737-740.
17. Ikeda I., Katayama T., Okahara M., Shono T. *Tetrahedron Lett.* **1981**, *22*, 3615-3616.
18. White B.D., Dishong D.M., Minganti C., Arnold K.A., Goli D.M., Gokel G.W. *Tetrahedron Lett.* **1985**, *26*, 151-154.
19. Zavada J., Koudelka J., Holy P., Belohradsky M., Stibor I. *Coll. Czech. Chem. Commun.* **1989**, *54*, 1043-1054.
20. Schultz R.A., White B.D., Dishong D.M., Arnold K.A., Gokel G.W. *J. Am. Chem. Soc.* **1985**, *107*, 6659-6668.
21. Dishong D.M., Diamond C.J., Cinoman M.I., Gokel G.W. *J. Am. Chem. Soc.* **1983**, *105*, 586-593.
22. Goli D.M., Dishong D.M., Diamond C.J., Gokel G.W. *Tetrahedron Lett.* **1982**, *23*, 5243-5246.
23. Nakatsuji Y., Nakamura T., Okahara M., Dishong D.M., Gokel G.W. *J. Org. Chem.* **1983**, *48*, 1237-1242.
24. Yakushev A.A., Chernichenko N.M., Anokhin M.V., Averin A.D., Buryak A.K., Denat F., Beletskaya I.P. *Molecules* **2014**, *19*, 940-965.
25. Kobelev S.M., Averin A.D., Buryak A.K., Denat F., Guillard R., Beletskaya I.P. *Macrocyclics* **2014**, *7*, 28-33.
26. Anokhin M.V., Averin A.D., Buryak A.K., Beletskaya I.P. *Mendeleev Commun.* **2011**, *21*, 132-133.
27. Anokhin M.V., Averin A.D., Beletskaya I.P. *Eur. J. Org. Chem.* **2011**, 6240-6253.
28. Anokhin M.V., Averin A.D., Panchenko S.P., Maloshitskaya O.A., Beletskaya I.P. *Russ. J. Org. Chem.* **2014**, *50*, 923-927.
29. Anokhin M.V., Averin A.D., Panchenko S.P., Maloshitskaya O.A., Buryak A.K., Beletskaya I.P. *Helv. Chim. Acta* **2015**, *98*, 47-59.
30. Kotovshchikov Yu.N., Latyshev G.V., Lukashev N.V., Beletskaya I.P. *Eur. J. Org. Chem.* **2013**, 7823-7832.
31. Ukai T., Kawazura H., Ishii Y., Bonnet J.J., Ibers J.A. *J. Organomet. Chem.* **1974**, *65*, 253-266.

Received 24.10.2014

Accepted 26.11.2014